Ocular Therapeutix (NASDAQ:OCUL) Shares Down 5.9%

Ocular Therapeutix Inc (NASDAQ:OCUL)’s stock price fell 5.9% during mid-day trading on Tuesday . The stock traded as low as $3.62 and last traded at $3.82, 990,851 shares traded hands during mid-day trading. An increase of 53% from the average session volume of 649,721 shares. The stock had previously closed at $4.06.

Several equities analysts have recently commented on the company. ValuEngine raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Piper Jaffray Companies set a $8.00 price target on Ocular Therapeutix and gave the company a “buy” rating in a research note on Friday, July 26th. Zacks Investment Research lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th. JMP Securities set a $9.00 price target on Ocular Therapeutix and gave the company a “buy” rating in a research note on Friday, June 21st. Finally, HC Wainwright set a $9.00 price target on Ocular Therapeutix and gave the company a “buy” rating in a research note on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $9.18.

The company has a 50 day moving average price of $4.35 and a 200 day moving average price of $4.12. The firm has a market cap of $180.05 million, a price-to-earnings ratio of -2.43 and a beta of 2.18. The company has a debt-to-equity ratio of 7.06, a quick ratio of 6.39 and a current ratio of 6.46.



Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.15). Ocular Therapeutix had a negative net margin of 3,450.84% and a negative return on equity of 256.69%. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $1.00 million. On average, research analysts forecast that Ocular Therapeutix Inc will post -1.59 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in OCUL. Bank of New York Mellon Corp lifted its stake in Ocular Therapeutix by 2.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 105,467 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 2,990 shares in the last quarter. BNP Paribas Arbitrage SA acquired a new position in Ocular Therapeutix during the 1st quarter worth about $30,000. Creative Planning acquired a new position in Ocular Therapeutix during the 2nd quarter worth about $52,000. Northern Trust Corp lifted its stake in Ocular Therapeutix by 3.3% during the 2nd quarter. Northern Trust Corp now owns 419,982 shares of the biopharmaceutical company’s stock worth $1,848,000 after acquiring an additional 13,249 shares in the last quarter. Finally, Highland Capital Management LLC acquired a new position in Ocular Therapeutix during the 2nd quarter worth about $62,000. 48.11% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile (NASDAQ:OCUL)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Read More: Net Asset Value

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.